Izalontamab brengitecan

Antibody–drug conjugate

Also known as BMS-986507

Approvedregulatory verdict

Evidence outlook

Approved: Adults with recurrent or metastatic esophageal squamous cell carcinoma after... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3 · investigational in the USNasopharyngeal Carcinoma · Phase 3 · investigational in the USEsophageal Squamous Cell Carcinoma · Phase 3 · investigational in the USOvarian Cancer · Phase 3 · investigational in the USBiliary Tract Cancer · Phase 3 · investigational in the USUrothelial Carcinoma · Phase 3 · investigational in the US

Also approved (2)
CN
  • Adults with recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapybiospace.com
  • Recurrent or metastatic nasopharyngeal carcinoma after prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapyprnewswire.com
Product first approved 2026

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (17)
Biliary Tract Cancer
NCT07582315 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-06-29 – 2028-12 · Biliary Tract Cancer
What this study did
Esophageal Squamous Cell Carcinoma
HR+/HER2- Metastatic Breast Cancer
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
NCT06838273 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-02-24 – 2028-12 · Non-small Cell Lung Cancer
What this study did
NCT06382116 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-05-22 – 2027-12 · Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT06994195 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-08-04 – 2027-12 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
Urothelial Carcinoma
NCT06857175 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-03-25 – 2027-12 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT07502300 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-06-15 – 2029-12 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT06382142 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-06-21 – 2027-12 · Triple-Negative Breast Cancer
What this study did
NCT06500026 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-08-07 – 2026-12 · Small Cell Lung Cancer
What this study did
Phase 2/3 (8)
Esophageal Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
NCT07642024 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-07-24 – 2032-12 · Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT07106762 · Bristol-Myers Squibb
2025-09-30 – 2033-11-18 · Urothelial Cancer
What this study did
Other / comorbidity
NCT07641855 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-09 – 2028-12 · Castration-resistant Prostate Cancer
What this study did
Phase 2 (27)
Biliary Tract Cancer
NCT06978114 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-06-10 – 2027-12 · Advanced Biliary Tract Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT06042894 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-12-12 – 2027-12 · Breast Cancer
What this study did
Nasopharyngeal Carcinoma
NCT07797881 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-09 – 2030-12 · Nasopharyngeal Carcinoma (NPC)
What this study did
Non-Small Cell Lung Cancer
NCT07941583 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-12-01 – 2030-06-01 · EGFR-Mutant NSCLC
What this study did
NCT06951464 · Sichuan University
2025-06-25 – 2029-03-05 · Non-Small Cell Lung Cancer
What this study did
NCT06475300 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-06-25 – 2028-12 · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
What this study did
NCT07827261 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-09 – 2028-12 · Non-small Cell Lung Cancer
What this study did
NCT05956587 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-01-29 – 2027-12 · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
What this study did
NCT05880706 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-07-19 – 2027-07 · Non-small Cell Lung Cancer
What this study did
NCT06498986 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-07-31 – 2027-06 · Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT06405425 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-05-29 – 2028-06 · Urothelial Carcinoma
What this study did
NCT05965856 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-12-11 – 2027-12 · Urothelial Carcinoma, Solid Tumor
What this study did
Other / comorbidity
NCT06471205 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-08-02 – 2028-06 · Triple-negative Breast Cancer
What this study did
NCT06437522 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-06-07 – 2028-06 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06006169 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-10-20 – 2027-12 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06008054 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-11-16 – 2027-12 · Esophageal Cancer, Gastric Cancer, Colorectal Cancer
What this study did
NCT05990803 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-11-06 – 2027-12 · Cervical Cancer
What this study did
NCT06962787 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-07-28 – 2027-12 · Renal Cancer
What this study did
NCT07054567 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-08-21 – 2027-12 · Cervical Cancer, Endometrial Cancer
What this study did
NCT06787664 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-01-16 – 2027-12 · Chordoma
What this study did
NCT06437509 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-06-13 – 2027-12 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT05924841 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-11-10 – 2027-12 · Small Cell Lung Cancer
What this study did
NCT05785039 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-04-20 – 2027-12 · Urinary System Tumor, Solid Tumor
What this study did
NCT06598787 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-10-17 – 2026-10 · Recurrent Glioblastoma
What this study did
Phase 1/2 (3)
HR+/HER2- Metastatic Breast Cancer
NCT06618287 · Bristol-Myers Squibb
2025-02-04 – 2031-02-26 · Lung Cancer, Breast Cancer
What this study did
Other / comorbidity
NCT07307053 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-01-01 – 2031-01-31 · Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors
What this study did
NCT05803018 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-06-25 – 2027-12 · Gynecological Malignant Tumor, Solid Tumor
What this study did
Phase 1 (6)
HR+/HER2- Metastatic Breast Cancer
NCT05470348 · Sichuan Baili Pharmaceutical Co., Ltd.
2022-08-11 – 2027-12 · Breast Cancer, Solid Tumor
What this study did
Non-Small Cell Lung Cancer
NCT05983432 · SystImmune Inc.
2023-08-08 – 2030-07-22 · Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Adenocarcinoma, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Triple Negative Breast Cancer
What this study did
NCT07382726 · M.D. Anderson Cancer Center
2026-05-15 – 2029-12-24 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05194982 · Sichuan Baili Pharmaceutical Co., Ltd.
2021-11-29 – 2027-12 · Locally Advanced or Metastatic Solid Tumor
What this study did
NCT05262491 · Sichuan Baili Pharmaceutical Co., Ltd.
2022-02-14 – 2027-12 · Gastrointestinal Tumor
What this study did
NCT05393427 · Sichuan Baili Pharmaceutical Co., Ltd.
2022-02-15 – 2025-12 · Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Biliary Tract Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Izalontamab Brengitecan: this drugPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6)
ZanidatamabApprovedMultispecific antibodyHER2Weak signal
NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023)
Futibatinib (Lytgobi)Phase 3Small moleculeFGFR (FGFR1/2/3/4)not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
TovecimigPhase 2/3Multispecific antibodyDLL4 x VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RamucirumabPhase 2Monoclonal antibodyVEGFR2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(55 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Izalontamab brengitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (18)
November 2026 (1)
Phase 3Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT06118333 · CT.gov ↗
What to watch
December 2026 (17)
Phase 1Locally Advanced or Metastatic Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05194982 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05470348 · CT.gov ↗
What to watch
Phase 1Gastrointestinal TumorRecruiting
Est. primary completion 2026-12 · NCT05262491 · CT.gov ↗
What to watch
Phase 1/2Gynecological Malignant Tumor, Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05803018 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06006169 · CT.gov ↗
What to watch
Phase 2Esophageal Cancer, Gastric Cancer, Colorectal CancerRecruiting
Est. primary completion 2026-12 · NCT06008054 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05965856 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12 · NCT05990803 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05956587 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06042894 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06405425 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06471205 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06437509 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05924841 · CT.gov ↗
What to watch
Phase 2Urinary System Tumor, Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05785039 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06500026 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06382129 · CT.gov ↗
What to watch
2027 (14)
May 2027 (5)
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2027-05 · NCT06978114 · CT.gov ↗
What to watch
Phase 2Renal CancerRecruiting
Est. primary completion 2027-05 · NCT06962787 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Endometrial CancerRecruiting
Est. primary completion 2027-05 · NCT07054567 · CT.gov ↗
What to watch
Phase 2Advanced Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05 · NCT06986785 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-05 · NCT06951464 · CT.gov ↗
What to watch
June 2027 (6)
Phase 2ChordomaActive not recruiting
Est. primary completion 2027-06 · NCT06787664 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06 · NCT06437522 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06475300 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06498986 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2027-06 · NCT06994195 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-06 · NCT06857175 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07 · NCT05880706 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-24 · NCT07382726 · CT.gov ↗
What to watch
2028 (9)
March 2028 (1)
Phase 2/3Breast NeoplasmsRecruiting
Est. primary completion 2028-03-13 · NCT06926868 · CT.gov ↗
What to watch
December 2028 (8)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07827261 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07554456 · CT.gov ↗
What to watch
Phase 2/3Castration-resistant Prostate CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07641855 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-12 · NCT07582315 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07648914 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-12 · NCT06838273 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-15 · NCT07100080 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-29 · NCT06855771 · CT.gov ↗
What to watch
2029 (6)
January 2029 (2)
Phase 2/3Urothelial CarcinomaRecruiting
Est. primary completion 2029-01-26 · NCT07106762 · CT.gov ↗
What to watch
Phase 1/2Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2029-01-31 · NCT07307053 · CT.gov ↗
What to watch
December 2029 (4)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12 · NCT07739186 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12 · NCT07739199 · CT.gov ↗
What to watch
Phase 3Triple-Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2029-12 · NCT07729956 · CT.gov ↗
What to watch
Phase 3Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2029-12 · NCT07502300 · CT.gov ↗
What to watch
2030 (4)
April 2030 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-20 · NCT05983432 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT07941583 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2030-12 · NCT07797881 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-12 · NCT07640789 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
December 2031 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-12-30 · NCT07680790 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-12 · NCT07642024 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 3Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2033-12 · NCT07783321 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026Filing acceptedChina accepts new drug applications for iza-bren in triple-negative breast cancer and non-small cell lung cancer
CN, NMPA · Sichuan Baili Pharmaceutical · Source ↗
26 February 2026Topline resultPhase III BL-B01D1-307 interim topline: iza-bren met dual primary endpoints (PFS and OS) in TNBC
CN · Sichuan Biokin Pharmaceutical (SystImmune parent) · Source ↗